Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION) - a Randomized, Prospective, Multicenter, Open-label, Controlled Phase III Trial

NCT07739914 is registered in ClinicalTrials.gov with Hannover Medical School as lead sponsor.

NCT NCT07739914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07739914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION) - a Randomized, Prospective, Multicenter, Open-label, Controlled Phase III Trial
Lead sponsor
Hannover Medical School
Phase
Phase 3
Overall status
Recruiting
Start date
August 19, 2026
Completion date
June 30, 2031
Enrollment
150 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

liver allograft, liver diseases, liver transplantation